DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,399,988 | +5.9% | 25,796 | +2.4% | 1.11% | +10.5% |
| Q2 2023 | $6,045,840 | -4.7% | 25,191 | +0.1% | 1.01% | -18.8% |
| Q1 2023 | $6,342,839 | -56.9% | 25,166 | -54.6% | 1.24% | -62.3% |
| Q4 2022 | $14,708,515 | -99.9% | 55,416 | -32.6% | 3.29% | -35.0% |
| Q3 2022 | $21,248,485,000 | +176.3% | 82,266 | +213.8% | 5.06% | +253.2% |
| Q1 2022 | $7,689,939,000 | +27408.3% | 26,216 | -69.1% | 1.43% | -64.7% |
| Q4 2021 | $27,955,000 | +0.3% | 84,966 | -7.2% | 4.06% | -10.1% |
| Q3 2021 | $27,861,000 | +16.2% | 91,516 | +2.5% | 4.52% | +18.4% |
| Q2 2021 | $23,969,000 | +70.3% | 89,316 | +42.9% | 3.81% | +51.5% |
| Q1 2021 | $14,071,000 | +34.7% | 62,516 | +33.0% | 2.52% | +47.4% |
| Q4 2020 | $10,444,000 | +78.4% | 47,016 | +72.9% | 1.71% | +60.5% |
| Q3 2020 | $5,855,000 | +51.1% | 27,190 | -2.9% | 1.06% | -2.0% |
| Q2 2020 | $3,874,000 | 0.0% | 27,990 | 0.0% | 1.09% | 0.0% |
| Q1 2020 | $3,874,000 | -10.5% | 27,990 | -0.7% | 1.09% | +24.3% |
| Q4 2019 | $4,327,000 | +6.8% | 28,190 | +0.5% | 0.87% | -4.2% |
| Q3 2019 | $4,051,000 | +1.0% | 28,050 | 0.0% | 0.91% | +16.5% |
| Q2 2019 | $4,009,000 | +9.0% | 28,050 | +0.7% | 0.78% | +5.5% |
| Q1 2019 | $3,677,000 | +18.7% | 27,850 | -7.3% | 0.74% | +6.6% |
| Q4 2018 | $3,098,000 | -5.1% | 30,050 | 0.0% | 0.70% | +13.7% |
| Q3 2018 | $3,265,000 | +10.1% | 30,050 | 0.0% | 0.61% | -2.5% |
| Q2 2018 | $2,965,000 | +0.8% | 30,050 | 0.0% | 0.63% | -2.0% |
| Q1 2018 | $2,942,000 | +4.4% | 30,050 | -1.0% | 0.64% | +12.3% |
| Q4 2017 | $2,817,000 | +8.2% | 30,350 | 0.0% | 0.57% | -1.0% |
| Q3 2017 | $2,603,000 | +1.3% | 30,350 | -0.3% | 0.58% | +0.7% |
| Q2 2017 | $2,569,000 | -77.1% | 30,450 | -76.8% | 0.57% | -76.5% |
| Q1 2017 | $11,242,000 | +29.5% | 131,450 | +17.8% | 2.44% | +15.4% |
| Q4 2016 | $8,683,000 | +4.5% | 111,550 | +5.2% | 2.11% | -8.3% |
| Q3 2016 | $8,313,000 | -33.6% | 106,050 | -14.4% | 2.31% | -23.8% |
| Q2 2016 | $12,518,000 | +15.8% | 123,950 | +8.8% | 3.03% | -3.2% |
| Q1 2016 | $10,809,000 | -3.0% | 113,950 | -5.0% | 3.13% | +19.3% |
| Q4 2015 | $11,140,000 | +28.4% | 119,950 | +17.8% | 2.62% | +28.7% |
| Q3 2015 | $8,674,000 | +25.6% | 101,800 | +26.1% | 2.04% | +40.8% |
| Q2 2015 | $6,907,000 | +0.8% | 80,700 | 0.0% | 1.45% | +6.6% |
| Q1 2015 | $6,851,000 | -1.8% | 80,700 | -0.9% | 1.36% | -3.8% |
| Q4 2014 | $6,976,000 | +19.2% | 81,400 | +5.7% | 1.41% | +9.0% |
| Q3 2014 | $5,850,000 | -10.3% | 77,000 | -7.0% | 1.29% | -12.4% |
| Q2 2014 | $6,519,000 | -1.7% | 82,800 | -6.3% | 1.48% | -7.7% |
| Q1 2014 | $6,630,000 | -22.6% | 88,400 | -20.3% | 1.60% | -21.7% |
| Q4 2013 | $8,561,000 | +45.0% | 110,900 | +30.2% | 2.04% | +27.1% |
| Q3 2013 | $5,906,000 | +31.8% | 85,200 | +20.3% | 1.61% | +21.2% |
| Q2 2013 | $4,482,000 | – | 70,800 | – | 1.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |